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It has been demonstrated that the Phellinus linteus (PL) mushroom, which mainly consists of polysaccharides, possesses antitumour
activity. The mechanisms of PL against malignant growth remain unknown. The anticancer drug doxorubicin (Dox) has been shown
to induce apoptosis via initiating a caspase cascade. In this investigation, we tested the effect of PL on Dox-induced apoptosis in
prostate cancer LNCaP cells. We showed that PL or Dox, at relatively low doses, does not induce apoptosis in the cells. However,
combination treatment with low doses of PL and Dox results in a synergistic effect on the induction of apoptosis. In this apoptotic
process, caspases 8, 3 and BID are cleaved, and the addition of caspase inhibitor z-VADfmk completely blocks apoptosis. In addition,
JNK is activated in response to PL or the combination treatment in LNCaP cells. The suppression of JNK partially inhibits the
induction of apoptosis elicited by the co-treatment. These findings indicate that PL has a synergistic effect with Dox to activate
caspases in prostate cancer LNCaP cells. Our study also suggests that PL has therapeutic potential to augment the magnitude of
apoptosis induced by antiprostate cancer drugs.
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A major challenge in the treatment of prostate cancer, especially
the hormonally refractory form, is the presence of genetic and
cellular abnormalities associated with tumorigenesis. Therefore,
development of less toxic, more effective treatments is necessary.
One strategy is to explore and understand the mechanisms of
action of natural medicines. Fungi, like yeast, algae, bacteria and
higher plants have been intensively investigated for antitumour
modality, because it appears that they are able to modulate the
body’s immune responses against tumours with very low toxic
potential (Oh et al, 1992; Song et al, 1995; Borchers et al, 1999; Han
et al, 1999). Studies indicate that the main components in these
basidiomycetes are polysaccharides (Lorenzen and Anke, 1998;
Reshetnikov et al, 2001; Wasser, 2002). Beta-glucocans isolated
from lentinan (Lentinus edodes), pachymaran (Poria cocos),
schizophyllan (Schizophyllum commune) and krestin (Coriolus
versicolor) have been demonstrated to stimulate lymphocytes and
elicit nonspecific immune-activities in various experimental
settings (Wasser, 2002). It has also been reported that Phellinus
linteus (PL) has the most potent effect among basidiomycetes in
antitumour action (Wasser, 2002). Studies have also shown that
PL extraction is able to strongly suppress the growth of various
tumours in vitro and in vivo (Chihara et al, 1969; Chung et al,
1982; Cun et al, 1994), including the induction of growth arrest or
apoptosis. However, the molecular signalling involved in PL-
mediated antitumour activity has not yet been fully explored.
Caspases are key apoptotic effectors and belong to a family of
cysteine-containing, aspartate-specific proteases (Alnemri et al,
1996; Nicholson and Thomberry, 1997). Caspases exist as dormant
proenzymes in cells and are activated through proteolysis. Once
activated, caspases cleave a host of cellular substrates, leading to
morphological hallmarks of apoptosis, including DNA fragmenta-
tion. In a caspase cascade, caspase 8 or 9 acts as the initiator,
whereas others (e.g., caspases 3 and 7) serve as effectors of
apoptosis (Cohen, 1997; Salvesen and Dixit, 1997). Several
anticancer drugs, such as doxorubicin (Dox), have been suggested
to elicit a caspase cascade, leading to apoptosis (Hannun, 1997; Los
et al, 1997). A low dose of Dox can activate the G1 checkpoint via a
p53-dependent pathway, and high doses of Dox cause apoptosis
(Hannun, 1997; Los et al, 1997). Studies have also shown that Dox
can synergise with other drugs to induce cytotoxic effects against
breast cancer, hepatocellular carcinoma and colon carcinoma
(Keane et al, 1999; Muzutani et al, 1999; Yamanaka et al, 2000;
Lacour et al, 2001). The combination treatment of Dox and TRAIL
dramatically augments the therapeutic effect against prostate
cancer (Wu et al, 2002).
JNK, a c-Jun NH2-terminal kinase, was discovered to bind to the
c-Jun transactivation domain and phosphorylate Ser-63, Ser-73
and some secondary sites (Devary et al, 1991; Hibi et al, 1993). JNK
is rapidly phosphorylated and subsequently activated in response
to various stimuli, including different types of stresses (Devary
et al, 1991; Hibi et al, 1993). Studies have shown that JNK can
promote apoptosis by regulating BID processing or c-FLIPL
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sdegradation (Derijard et al, 1994; Davis, 2000). Upon activation,
JNK phosphorylates Itch (a E3-related ligase) and accelerates the
decay of c-FLIPL, which augments caspase 8 activity and allows
apoptosis to proceed (Gao et al, 2004; Chang et al, 2006).
Based on the information that Dox can synergise with TRAIL to
elicit cytotoxicity in various types of tumours (Hannun, 1997; Los
et al, 1997; Keane et al, 1999; Muzutani et al, 1999; Yamanaka et al,
2000; Lacour et al, 2001; Wu et al, 2002) as well as that PL is able to
interfere with tumour growth, we tried to explore the potential of
the combination treatment of Dox and PL against prostate cancer.
We examined LNCaP prostate cancer cells looking for evidence
of synergy between Dox and PL, and specifically to identify the
molecular mechanisms underlying this synergistic effect. In the
cells tested, PL enhanced Dox-induced cell death, possibly via
caspase-mediated apoptotic signalling pathways. During this
process, caspases 8, 3 and BID were activated by the combination
treatment of low doses of PL and Dox. The apoptotic process could
be blocked by the addition of caspase inhibitor z-VADfmk.
Phellinus linteus itself could also upregulate JNK activity and
further reduce the expression level of c-FLIPL. In addition, the
suppression of JNK partially blocked apoptosis induced by the
combination treatment of PL and Dox. The data suggest that PL
may act through interfering with antiapoptotic factor c-FLIPL to
sensitise Dox-mediated apoptotic signalling. Our study also
implies that the combination of PL and Dox may have potential
for the development of a more effective treatment against prostate
cancer.
MATERIALS AND METHODS
Cell culture and treatments
The human prostate cancer LNCaP cells were purchased from
American Tissue Culture Collection (Rockville, MD, USA) and
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% heat-inactivated fetal calf serum (FCS)
2m ML -glutamine, 100Uml
 1 of penicillin, 100gml
 1 of strepto-
mycin. Normal human prostate epithelial PrEC cells (Cambrex,
One Meadowlands Plaza, East Rutherford, NJ, USA) were cultured
in the PrEGM medium (Cambrex, NJ, USA). Whole powdered PL
that had been grown on germinated brown rice was purchased
from Panbio-Tech (Taejon, Korea), and purified using ethanol
precipitation methods, followed by DEAE-cellulose and gel
permeation chromatography (Song et al, 1995). The purified
components of PL mostly consist of polysacharides. Doxorubicin
was purchased from Sigma, St Louis, MO, USA.
Flow cytometric determination of nuclear DNA
fragmentation assay
A flow cytometric analysis was performed with a FACScan
(Becton-Dickenson, Mountain View, CA, USA). The data analysis
and display were performed using the Cell-Fit software program
(Becton-Dickenson). Cell-Fit interprets data from the flow
cytometer and provides real-time statistical analysis of the data,
computed at 1s intervals and also discriminates doublets or
adjacent particles. Briefly, following various treatments, cells
(1 10
6ml
 1) were washed with 1 phosphate–buffered saline
(PBS), fixed with 70% ethanol, and treated with 10ngml
 1 RNAse.
Subsequently, cells were stained with propidium iodide
(5mgml
 1). The stained samples were kept in the dark at 41C
overnight before flow cytometric analysis.
[
3H]Thymidine incorporation assay
After treatment, cells growing in 24-well plates were starved for
48h. The growth medium containing [
3H]thymidine (2mCiml
 1)
was then added, with or without treatment. Twenty-four hours
later, the medium was aspirated and cells were fixed. After washing
with 1ml of 5% trichloroacetic acid, cells were solubilised in 1%
sodium dodecyl sulphate (SDS) and 0.3nM NaOH. Incorporated
radioactivity was determined by scintillation counter.
Immunoblot
After treatment, cells were washed in 1 PBS and then lysed in the
lysis buffer (50mM Tris-HCl, pH 8.0, 150mM NaCl, 1% Triton X-
114, 0.5% sodium deoxycholate, 0.1% SDS, containing 1mM
phenylmethylsulphonyl fluoride, 1mgml
 1 aprotinin, 1mgml
 1
leupeptin, 1mgml
 1 pepstatin A) on ice for 30min. The total
protein concentrations in the cell lysates were normalised and
adjusted to 0.4 M NaCl, 0.5% deoxycholate and 0.05% SDS for
immunoblotting (Denis et al, 2003). The samples were separated
on a 10% SDS–polyacrylamide gel electrophoresis gel and
subsequently transferred to a nitrocellulose membrane. All the
antibodies used were purchased from BD Biosciences (San Diego,
CA, USA).
Caspase activity assay
After various treatments, lysates were prepared and the activities
of caspases 3 and 8 were measured by a colorimetric analysis (Wu
et al, 2001).
Preparation of subcellular fractions
After the treatments, cells (1 10
7) were washed twice with
1 PBS and resuspended in 1ml of 1% Triton X-114 lysis buffer
(Denis et al, 2003). The cell suspensions were transferred to a 1-ml
syringe and sheared by being passed 40 times through a 25-G
needle. The lysates were centrifuged at 280g for 10min, and the
supernatant was centrifuged at 16000g for 30min. Afterwards,
the supernatant was collected as the cytosolic fraction. For the
mitochondrial fraction, the cells (1 10
9) were resuspended in
buffer A (50mM Tris, pH 7.5, 1mM ethyleneglycol tetraacetate,
5m M 2-mercaptoethanol, 0.2% bovine serum albumin, 10mM
KH2PO4, pH 7.6, 0.4 M sucrose), and allowed to swell on ice for
40min. After centrifugation, the resulting pellets were resuspended
in buffer B (10mM KH2PO4, pH 7.2, 0.3mM mannitol, 0.1% bovine
serum albumin). The mitochondrial fractions were subsequently
separated on a sucrose step gradient (Denis et al, 2003).
Soft agar assay
Petri dishes were first layered with 0.6% basal agar dissolved in
DMEM medium containing 10% FCS. Cells were mixed in 0.33%
agar dissolved in DMEM medium containing PL (1mgml
 1). The
plates were incubated at 371C in a humidified atmosphere for 14
days. Fresh medium (2ml) containing PL (1mgml
 1) was added
to the cultures every 3 days.
RESULTS
PL mushroom and doxorubicin, at a low dose, synergise to
induce apoptosis in prostate cancer cells
It is known that PL can interfere with tumour proliferation, and
the antitumour effect of PL has been indicated to be related to the
contents of polysacharides (Chihara et al, 1969; Chung et al, 1982;
Cun et al, 1994). However, the mechanisms of PL that suppress
tumour growth remain unknown. To further investigate the
antitumour effect of PL in prostate cancer, we tested the effect of
the combination treatment of PL and Dox, at a low dose range, on
human prostate cancer LNCaP cells that have been shown to be
sensitive to Dox treatment (Hannun, 1997; Los et al, 1997; Keane
et al, 1999; Muzutani et al, 1999; Yamanaka et al, 2000; Lacour
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set al, 2001; Wu et al, 2002). LNCaP cells were either left untreated,
or treated with different doses of PL, Dox or the combination of
these two for 48h. Afterwards, a DNA fragmentation assay was
conducted (Figure 1A). Under normal growth conditions, only a
few untreated LNCaP cells had fragmented DNA. After treatment
with PL alone, the percentage of DNA fragmentation was
moderately increased in a dose-dependent manner. A similar
phenomenon was observed following Dox treatment; low doses of
Dox had a minor apoptotic effect on the cells. In comparison,
treatment with high doses of Dox (42mgml
 1) for 24h caused
more than 40% of the cells to have fragmented DNA, also in a
dose-dependent manner. As low doses of PL or Dox could not
induce apoptosis, we tested whether the combination of these two
would affect cell viability. The cells were treated with 0.25 or
0.5mgml
 1 of PL plus 1mgml
 1 of Dox. Twenty-four hours after
the combination treatment, the percentage of DNA fragmentation
was analysed. A significant synergy of PL and Dox in the induction
of apoptosis was observed. Normal prostate epithelial PrEC cells
were also used for testing the synergistic effect on the induction of
apoptosis (Figure 1B). Neither the drug alone nor the combination
treatment elicited apoptosis in the normal cells. To further define
the growth pattern of PrEC cells in response to the combination
treatment, a [
3H]thymidine incorporation assay was performed
(Figure 1C). Serum-starved PrEC cells incorporated a large amount
of [
3H]thymidine into their genome after adding the growth
medium containing 10% serum. In contrast, cells under the same
growth conditions did not incorporate [
3H]thymidine in response
to the treatment of PL, Dox or both. Overall, the results indicate
that PL, at low doses, can render the prostate cancer cells, but not
the normal prostate epithelial cells, susceptible to Dox-induced
apoptosis.
To further define the long-term effect of the combination
treatment of PL and Dox on tumour growth, a soft agar assay was
performed (Table 1). Untreated LNCaP cells formed colonies in
soft agar medium. Interestingly, although low doses of PL or Dox
did not affect the viability of the cells (see Figure 1), it moderately
blocked the formation of the colonies. This may be due to the
drugs’ negative effect on cell cycle progression (Hannun, 1997; Los
et al, 1997), which inhibits the cells from forming colonies. The
high dose of Dox treatment (5mgml
 1) completely prevented the
cells from forming colonies. The combination treatment of the low
doses of PL and Dox achieved a prominent blocking effect on
colony formation. Thus, the data suggest the existence of a
synergistic, cytotoxic effect of PL and Dox, at low doses, on
prostate cancer cells.
Involvement of caspases in the synergistic effect of PL and
Dox
The caspase cascade plays an important role in many types of
apoptosis, including Dox-induced apoptosis (Hannun, 1997; Los
et al, 1997). It is known that Dox, at high doses, can induce
apoptosis, possibly through caspase-mediated apoptotic signalling,
including caspase 8 (Hannun, 1997; Los et al, 1997). To determine
whether and which caspases are involved in the synergistic
induction of apoptosis by PL and Dox, our primary focus was to
study the mechanisms of the combination treatment of PL and Dox
on several caspase family members. Caspases, upon activation, are
cleaved into a small, active form (Hannun, 1997; Los et al, 1997).
Therefore, immunoblot analysis was employed using caspases 3, 8
and BID antibodies to detect the presence and levels of the
corresponding proteins following various treatments (Figure 2A).
The active, cleaved forms of caspases 3, 8 and BID were absent in
LNCaP cells upon treatment with low doses of PL or Dox. In
comparison, the caspases were significantly activated in response
to the combination treatment. To further determine the activation
of caspases by the co-treatment of PL and Dox, the activities of
caspases 3 and 8 were measured using an enzymatic assay
(Figure 2B). Again, the activities of these proteases were
undetectable following treatment with low doses of PL or Dox
alone. The combination treatment dramatically upregulated the
activities of these caspases.
Cytochrome c is an apoptotic executor during the process of
caspase-mediated apoptosis. Therefore, the release of cytochrome c
from the mitochondria to the cytosol in response to various
treatments was also examined in LNCaP cells (Figure 3). After
isolating the cytosolic or mitochondrial fractions from untreated
or treated LNCaP cells, immunoblotting was performed using an
anti-cytochrome c antibody. Cyctochrome c was present in the
cytosolic fraction isolated from the cells treated with the
combination of PL and Dox, but not in the cells either untreated
or treated with PL or Dox alone (Figure 3, upper panel). Also, after
the addition of low doses of PL plus Dox, the anti-cytochrome c
antibody could not detect the protein in the mitochondrial fraction
of the cells, but the protein was present in the mitochondrial
fraction of either untreated cells or cells treated with PL or Dox
(Figure 3, lower pannel). Overall, these results indicate that low
doses of PL and Dox can synergise to enhance caspase activity in
LNCaP cells.
JNK is activated and controls FLIPL expression in response
to PL or PL plus Dox
JNK, a stress-related kinase, requires phosphorylation to be
activated and is often involved in the modulation of various types
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Figure 1 DNA fragmentation and [
3H]thymidine incorporation in
response to the treatment of PL, Dox and PL plus Dox. (A) and (B)
LNCaP or PrEC cells were cultured in the growth medium in the presence
of different concentrations of PL, Dox, or PL plus Dox. After treatment for
48h, the percentage of cells with fragmented DNA was analysed by a flow
cytometer. Error bars represent the s.d. over five independent experi-
ments. (C) Following serum-starvation (0.5% serum) for 48h, the cells
were refed with growth medium containing 10% serum and [
3H]thymidine
(2mCiml
 1) in the presence or absence of PL, Dox or both for 24h.
Subsequently, trichloroacetic acid-insoluble radioactivity was determined.
Error bars represent the s.d. from five independent experiments.
Table 1 Colony formation of LNCaP cells in soft agar
Treatment No. of colonies s.d.
No treatment 174 77.5
PL (0.5mgml
 1)8 7 75
Dox (1.0mgml
 1)6 5 70.2
Dox (5.0mgml
 1)0 70.8
PL (0.5mgml
 1)+Dox (1mgml
 1)4 70.5
Dox¼doxorubicin; PL¼Phellinus linteus. The cells were cultured in soft agar in the
presence of PL, Dox, or the combination of PL and Dox for 2 weeks. s.d.: standard
deviation over five independent experiments.
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sof apoptosis, including those induced by caspases (Davis, 2000). It
has been shown that JNK activation in tumour necrosis factor
(TNF)a-induced apoptotic processes promotes the activity of
caspases by regulating the expression level of c-FLIPL, a caspase
cascade inhibitor (Chang et al, 2006). To determine the JNK
activation status in our experimental settings, the expression of
JNK was analysed by immunoblotting using an anti-JNK antibody.
JNK protein expression was detectable in untreated LNCaP cells or
cells treated with Dox (Figure 4A, upper panel). In comparison,
PL treatment alone or the combination treatment augmented
the expression of this kinase. As JNK is phosphorylated upon
activation, its phosphorylation status was then determined using
the anti-phos-JNK antibody (Figure 4A, lower panel). The
phosphorylated JNK was recognised by the antibody in the cells
treated with PL alone or co-treated with PL plus Dox. JNK was not
activated by the addition of Dox alone.
JNK has been demonstrated to regulate the degradation of c-
FLIPL that is an important negative regulator of caspase 8 and
further controls the expression of the protein (Chang et al, 2006).
We conducted immunoblotting experiments to test the expression
of c-FLIPL in LNCaP cells (Figure 4B). The amount of c-FLIPL
expression in the cells treated with Dox alone was the same as that
in untreated cells. However, c-FLIPL expression was dramatically
suppressed by PL or the combination treatment. In addition,
blockade of JNK expression by introduction of a dominant-
negative JNK into the cells lifted the inhibitory effect on the
expression of c-FLIPL rendered by the treatment with PL or PL
plus Dox. The data suggest that PL, via regulating JNK activation
and subsequent c-FLIPL expression, synergises with Dox for the
initiation of a caspase cascade.
To further determine the nature of the synergistic effect of PL on
Dox-induced apoptosis, a DNA fragmentation assay was con-
ducted in the presence of caspase or JNK inhibitors (Figure 5). A
general caspase inhibitor z-VADfmk completely blocked the
apoptotic process induced by the co-treatment with PL and Dox.
Furthermore, the magnitude of apoptosis elicited by the combina-
tion treatment was significantly suppressed by the addition of a
JNK inhibitor or the introduction of a dn-JNK into LNCaP cells,
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PL (0.5 mg ml −1 )
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Caspase 8 (p17) 
Caspase 8 (p42)
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A
Figure 2 Activation of caspase 3, 8 or BID following the treatmet with PL, Dox or PL plus Dox. (A) After treating with PL, Dox, or PL plus Dox, LNCaP
cells were harvested and lysates were prepared. The existence of activated forms of caspases 3, 8 and BID was determined by Western blot. Equal loading of
total proteins was verified by b-Actin expression. (B) Following the treatments, lysates were prepared to measure the activity of these caspase family
members using a colorimetric assay. Error bars represent the s.d. over five independent experiments.
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swhich again supports the notion that PL, via activating JNK and
further blocking c-FLIPL, potentiates Dox-induced apoptosis.
DISCUSSION
In the apoptotic process induced by the co-treatment of PL and
Dox, caspase 8 is activated, which then initiates a caspase cascade,
resulting in the release of cytochrome c from the mitochondria
to the cytosol. The suppression of caspase activity by a generic
caspase inhibitor z-VADfmk completely abolishes apoptosis
induced by the co-treatment. Furthermore, the addition of PL
alone is able to cause JNK activation, which subsequently
downregulates the expression level of c-FLIPL in the cells. The
addition of a JNK inhibitor or introduction of a dn-JNK suppresses
the apoptotic process induced by the co-treatment. Therefore, our
findings suggest that PL is a useful synergiser for augmenting Dox-
mediated, apoptotic signalling. As such synergy on the induction
of apoptosis only requires low doses of Dox, PL has potential for
further developing a better therapeutic strategy to treat prostate
cancer and avoid the side effects caused by high doses of Dox.
Because prostate cancer progression is partially affected by
development of resistance of the cancer cells to apoptosis induced
by anticancer drugs, the ability to sensitise apoptotic signalling
pathways has important therapeutic implications. Genetic target-
ing or pharmacological manipulation of caspase family members
and their regulators/modulators would provide better clinical
strategies. Targeting the expression of caspase 7 has been
demonstrated to be a useful approach for treating prostate cancer
(Marcelli et al, 1998, 1999). In this approach, overexpression of
caspase 7 in LNCaP cells could effectively induce apoptosis and has
been shown to be very promising clinically (Marcelli et al, 1998,
1999). Therefore, the combination treatment of low doses of PL
and Dox to activate caspases would have similar implications for
treating prostate cancer patients.
Studies using specific caspase inhibitors have shown that Dox
can activate caspases 8, 6 and 3 (Hannun, 1997; Los et al, 1997).
The synergistic effect of Dox and TRAIL on caspase-induced
apoptosis has been reported (Wu et al, 2002). Here, we
demonstrated that Dox is also able to synergise with PL at low
doses for the induction of apoptosis. In this apoptotic process,
caspases 3, 8 and BID are activated, leading to the release of
cytochrome c from the mitochondria to the cytosol. A generic
caspase inhibitor blocked this synergistic, apoptotic effect on
LNCaP cells, further suggesting the involvement of caspase activity
in the cytotoxicity rendered by the combination treatment with PL
and Dox. However, at low doses neither Dox nor PL elicited the
Cyto c
Bcl-2
Mitochondria
Cyto c
Tubulin
Cytosol
Dox (1.0 g ml−1)
Ctrl
PL (0.5 mg ml−1)
PL (0.5 mg ml−1 + Dox (1.0 g ml−1)
Dox (1.0 g ml−1)
Ctrl
PL (0.5 mg ml−1)
PL (0.5 mg ml−1 + Dox (1.0 g ml−1)
Figure 3 Releasing of cytochrome c to the cytosol following the
treatment with PL, Dox, or PL plus Dox. The mitochondrial or cytosolic
fractions from untreated or treated cells were isolated and analysed for the
expression of cytochrome c by Western blot. Equal loading of proteins in
the mitochondrial or cytosolic fraction was determined by reprobing the
blot with antitubulin or Bcl-2 Ab.
b
c-FLIPL
Actin
Dox (1.0 g ml−1)
Ctrl
PL (0.5 mg ml−1)
PL (0.5 mg ml−1 + Dox ( 1.0 g ml−1)
PL (0.5 mg ml−1)
PL (0.5 mg ml−1 + Dox (1.0 g ml−1)
dnJNK
p-JNK
JNK
Actin
Dox (1.0 g ml−1)
Ctrl
PL (0.5 mg ml−1)
PL (0.5 mg ml−1 + dox (1.0 g ml−1)
Dox (1.0 g ml−1)
Ctrl
PL (0.5 mg ml−1)
PL (0.5 mg ml−1 + Dox (1.0 g ml−1)
a
Figure 4 JNK activation and c-FLIPL expression. (A) After treatment
with PL, Dox or PL plus Dox, cells were harvested and lysates were
prepared. The protein expression level of JNK or the presence of the
phosphorylated form of JNK was determined by Western blot using the
corresponding antibodies. Equal loading of total proteins in each sample
was verified by b-actin. (B) c-FLIPL expression upon treatment with PL,
Dox, or PL plus Dox. The cells with or without addition of a dn-JNK were
treated with PL, Dox, or PL plus Dox. Subsequently, lysates were prepared
to analyse the expression level of c-FLIPL. The percentages of the cells with
fragmented DNA were determined by flow cytometry. The error bars
represent the s.d. over five independent experiments.
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sactivity of these caspase family members to induce apoptosis. It is
possible that treatment with PL at low doses reduces the threshold
of the sensitivity of LNCaP cells to Dox-induced apoptosis.
JNK is activated in response to various stresses. The exact
mechanisms through which JNK participates in apoptosis remain
unknown. JNK is not a direct apoptotic executor, however, instead,
it often modulates the initiation of apoptosis through promoting
processing of proapoptotic factors, such as the BH3-domain
proteins or decaying of antiapoptotic factors (Luo et al, 1998). In
caspase-induced apoptosis, JNK has been suggested to act at a step
upstream to caspase 8 (Deng et al, 2003). Recently, experiments,
in vitro and in vivo, have shown that JNK, during TNFa-induced
apoptotic processes, activates ubiquitin ligase Itch, which speci-
fically interacts with c-FLIPL to promote the degradation of this
caspase inhibitor (Chang et al, 2006). In our experimental settings,
a low dose of PL was enough to elicit JNK phosphorylation, but
not to induce apoptosis. However, this activation of JNK was
responsible for the reduction of c-FLIPL expression in LNCaP
cells. Therefore, JNK, by promoting the degradation process,
suppresses c-FLIPL, and may sensitise the prostate cancer cells to
apoptosis. Doxorubicin is known to be able to elicit cellular or
DNA damage-induced responses at low-dose ranges and mobilise
caspase family members to execute cell death programs at high-
dose ranges. It is well possible that JNK, by lowering the threshold
of LNCaP cells to apoptosis, synergises with Dox for the activation
of caspases.
Phellinus linteus and Dox, at low doses, are G1 arrest inducers
(Guo et al, 2006). The data from colony formation assays
demonstrated that LNCaP cells formed fewer colonies in soft agar
medium in the presence of a low dose of Dox or PL alone. In
contrast, the combination treatment with these two agents at low
doses blocks LNCaP cells from growing and forming colonies in
soft agar medium. The reduction of the numbers of colonies
following treatment with Dox or PL alone at low concentrations is
highly likely due to a negative effect of the treatment on cell
proliferation, resulting in slow formation of colonies. In addition,
the combination treatment of low doses of PL and Dox is nontoxic
to normal prostate epithelial cells, causing only growth cessation.
This suggests that PL can selectively sensitise cancer cells for
apoptotic signalling.
The development of chemotherapeutic resistance to drugs is a
major obstacle to the successful treatment of prostate cancer. A
more effective anticancer therapy is required. Our present study
demonstrates that PL acts as an enhancer to sensitise Dox-
mediated, apoptotic signalling, and this sensitisation can be
obtained at subtoxic concentrations of Dox. We previously have
reported that PL, even at high doses, only causes normal
fibroblasts or lung epithelial cells to arrest in the G1 phase of the
cell cycle (Guo et al, 2006). Altogether, our data suggest that PL is
an apoptotic synergiser for conventional chemotherapeutics such
as Dox, which can keep normal, surrounding cells unharmed.
Therefore, PL, serving as a safe alternative medicine, has potential
for more efficient therapies against drug-resistant prostate cancer.
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